Health News Roundup: J&J effort to resolve talc lawsuits in bankruptcy fails a second time; AstraZeneca's rare disease arm in $1 billion deal for Pfizer gene therapies and more devdiscourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from devdiscourse.com Daily Mail and Mail on Sunday newspapers.
Health News Roundup: AstraZeneca's rare disease arm in $1 billion deal for Pfizer gene therapies; Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio and more devdiscourse.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from devdiscourse.com Daily Mail and Mail on Sunday newspapers.
Sharon Barr Named AstraZeneca EVP BioPharmaceuticals R&D miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
(Reuters) -AstraZeneca said on Friday its Alexion unit had agreed to buy U.S. drugmaker Pfizer's early-stage rare disease gene therapy portfolio for up to $1 billion, plus royalties on sales, as the British drugmaker bets on new genetic therapies. The British company also said Sharon Barr, head of research and development at Alexion, would succeed Mene Pangalos, the long-time biopharmaceuticals head of research at AstraZeneca.